COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions.
作者信息
Kirkcaldy Robert D, King Brian A, Brooks John T
机构信息
US Centers for Disease Control and Prevention, Atlanta, Georgia.
出版信息
JAMA. 2020 Jun 9;323(22):2245-2246. doi: 10.1001/jama.2020.7869.
Abstract
摘要
相似文献
1
COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions.新冠病毒感染与感染后免疫：证据有限，仍有诸多问题
JAMA. 2020 Jun 9;323(22):2245-2246. doi: 10.1001/jama.2020.7869.
2
Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection.新型冠状病毒血清中和抗体的持续时间：严重急性呼吸综合征冠状病毒感染的经验教训。
J Microbiol Immunol Infect. 2020 Oct;53(5):821-822. doi: 10.1016/j.jmii.2020.03.015. Epub 2020 Mar 25.
3
COVID-19 and the Path to Immunity.新冠病毒肺炎与免疫之路
JAMA. 2020 Oct 6;324(13):1279-1281. doi: 10.1001/jama.2020.16656.
4
Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者的抗严重急性呼吸综合征冠状病毒2抗体反应
Leukemia. 2020 Nov;34(11):3047-3049. doi: 10.1038/s41375-020-01030-2. Epub 2020 Aug 27.
5
Protective humoral immunity in SARS-CoV-2 infected pediatric patients.新冠病毒感染的儿科患者中的保护性体液免疫
Cell Mol Immunol. 2020 Jul;17(7):768-770. doi: 10.1038/s41423-020-0438-3. Epub 2020 May 7.
6
Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients.无症状感染者感染 SARS-CoV-2 8 周后的抗体反应。
Emerg Infect Dis. 2020 Oct;26(10):2484-2487. doi: 10.3201/eid2610.202211. Epub 2020 Jun 24.
7
Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate.中和抗体与高感染率渔业船舶暴发期间人类免受 SARS-CoV-2 感染相关。
J Clin Microbiol. 2020 Oct 21;58(11). doi: 10.1128/JCM.02107-20.
8
The Ethics of COVID-19 Immunity-Based Licenses ("Immunity Passports").基于新冠病毒免疫力的许可（“免疫通行证”）的伦理问题。
JAMA. 2020 Jun 9;323(22):2241-2242. doi: 10.1001/jama.2020.8102.
9
Low prevalence of IgG antibodies to SARS-CoV-2 in cancer patients with COVID-19.新冠病毒疾病（COVID-19）癌症患者中抗SARS-CoV-2 IgG抗体的低流行率。
Int J Cancer. 2020 Dec 1;147(11):3267-3269. doi: 10.1002/ijc.33148. Epub 2020 Jun 27.
10
Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders.血清 IgG 对轻度和重度 COVID-19 感染后 SARS-CoV-2 的反应以及 IgG 无应答者的分析。
PLoS One. 2020 Oct 21;15(10):e0241104. doi: 10.1371/journal.pone.0241104. eCollection 2020.
引用本文的文献
1
Fuzheng Xuanfei Huashi prescription suppresses inflammation in lipopolysaccharide-induced lung injury in mice toll-like recptor 4/nuclear transcription factor κB and cyclooxygenase-2/prostaglandin E2 pathway.扶正宣肺化湿方通过Toll样受体4/核转录因子κB和环氧化酶-2/前列腺素E2通路抑制脂多糖诱导的小鼠肺损伤中的炎症反应。
J Tradit Chin Med. 2025 Apr;45(2):272-280. doi: 10.19852/j.cnki.jtcm.2025.02.018.
2
T Cell Peptide Prediction, Immune Response, and Host-Pathogen Relationship in Vaccinated and Recovered from Mild COVID-19 Subjects.T 细胞肽预测、免疫反应以及接种疫苗和从轻度 COVID-19 中康复的受试者中的宿主-病原体关系。
Biomolecules. 2024 Sep 26;14(10):1217. doi: 10.3390/biom14101217.
3
Mathematical modelling of COVID-19 transmission dynamics in a partially comorbid community.部分共病社区中新冠病毒传播动力学的数学建模
Partial Differ Equ Appl Math. 2022 Jun;5:100212. doi: 10.1016/j.padiff.2021.100212. Epub 2021 Nov 24.
4
COVID-19 natural herd immunity and risk of neuropsychiatric disorders.新冠病毒感染后的群体自然免疫与神经精神疾病风险
Rev Psiquiatr Salud Ment. 2020 Oct-Dec;13(4):228-229. doi: 10.1016/j.rpsm.2020.07.002. Epub 2020 Aug 24.
5
An Outbreak Preparedness and Mitigation Approach in Home Health and Personal Home Care During the COVID-19 Pandemic.新冠疫情期间家庭健康与个人居家护理中的疫情防范与缓解措施
Home Health Care Manag Pract. 2020 Nov;32(4):229-233. doi: 10.1177/1084822320933567.
6
Causes and Effects of COVID-19 Vaccine Hesitancy Among Pregnant Women and its Association with Adverse Maternal, Placental, and Perinatal Outcomes.COVID-19 疫苗犹豫在孕妇中的原因和影响及其与不良母婴、胎盘和围产结局的关联。
Yale J Biol Med. 2024 Mar 29;97(1):73-84. doi: 10.59249/LPOQ5146. eCollection 2024 Mar.
7
Epidemiological contemplation for a currently pragmatic COVID-19 health passport: a perspective.对当前实用主义的 COVID-19 健康护照的流行病学思考：一个观点。
Front Public Health. 2024 Feb 13;12:1347623. doi: 10.3389/fpubh.2024.1347623. eCollection 2024.
8
Cellular and Molecular Mechanisms of Pathogenic and Protective Immune Responses to SARS-CoV-2 and Implications of COVID-19 Vaccines.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的致病性和保护性免疫反应的细胞和分子机制以及2019冠状病毒病（COVID-19）疫苗的影响
Vaccines (Basel). 2023 Mar 8;11(3):615. doi: 10.3390/vaccines11030615.
9
Epidemiologic and clinical characteristics of patients with COVID-19 in hospitals in Sirjan at 2020.2020年锡尔詹医院新冠肺炎患者的流行病学和临床特征
J Educ Health Promot. 2022 Oct 31;11:352. doi: 10.4103/jehp.jehp_652_21. eCollection 2022.
10
Population-based sero-epidemiological investigation of the dynamics of SARS-CoV-2 infections in the Greater Accra Region of Ghana.加纳大阿克拉地区基于人群的 SARS-CoV-2 感染动态血清流行病学调查。
Sci Rep. 2022 Dec 14;12(1):21582. doi: 10.1038/s41598-022-25598-0.
本文引用的文献
1
False negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence.2019冠状病毒病中逆转录聚合酶链反应的假阴性及核酸转换延长：而非复发
J Med Virol. 2020 Oct;92(10):1755-1756. doi: 10.1002/jmv.25855. Epub 2020 Jul 11.
2
Virological assessment of hospitalized patients with COVID-2019.住院 COVID-19 患者的病毒学评估。
Nature. 2020 May;581(7809):465-469. doi: 10.1038/s41586-020-2196-x. Epub 2020 Apr 1.
3
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019.新型冠状病毒病 2019 患者的 SARS-CoV-2 抗体反应。
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034. doi: 10.1093/cid/ciaa344.
4
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.SARS-CoV-2 感染后口咽后唾液样本和血清抗体反应中的病毒载量时间特征：一项观察性队列研究。
Lancet Infect Dis. 2020 May;20(5):565-574. doi: 10.1016/S1473-3099(20)30196-1. Epub 2020 Mar 23.
5
Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China, January to February 2020.2020 年 1 月至 2 月，中国两例新冠肺炎（COVID-19）治愈医务人员出院后随访和病毒阳性检出情况。
Euro Surveill. 2020 Mar;25(10). doi: 10.2807/1560-7917.ES.2020.25.10.2000191.
6
Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.新加坡 2019 年新型冠状病毒肺炎患者的流行病学特征和临床病程
JAMA. 2020 Apr 21;323(15):1488-1494. doi: 10.1001/jama.2020.3204.
7
Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus.中东呼吸综合征冠状病毒抗体的持续性
Emerg Infect Dis. 2016 Oct;22(10):1824-6. doi: 10.3201/eid2210.160706. Epub 2016 Oct 15.
8
Duration of antibody responses after severe acute respiratory syndrome.严重急性呼吸综合征后抗体反应的持续时间。
Emerg Infect Dis. 2007 Oct;13(10):1562-4. doi: 10.3201/eid1310.070576.
Zotero 插件